PG
ADPT icon

Pendal Group’s Adaptive Biotechnologies ADPT Stock Holding History

Pendal Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,576
Closed -$448K – 531
2020
Q4 		$448K Buy
7,576
+15
+0.2% +$773 ﹤0.01% 386
2020
Q3 		$368K Buy
+7,561
New +$318K ﹤0.01% 345
2019
Q3 		– Sell
-114
Closed -$5.51K – 448
2019
Q2 		$5.51K Buy
+114
New +$5.05K ﹤0.01% 427

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Pendal Group's ADPT Position: Q1 2021 in Review

Pendal Group sold out of Adaptive Biotechnologies (ADPT) in Q1 2021, closing a stake of 7,576 shares — an estimated $448K sold.

Pendal Group first reported a position in ADPT in Q2 2019 and held it in 3 quarters. The position peaked at $448K in Q4 2020. 248 funds tracked by Wall St. Rank hold ADPT as of Q1 2021.

  • Pendal Group reported no remaining Adaptive Biotechnologies position as of Q1 2021 after selling out during the quarter.
  • Pendal Group sold 7,576 Adaptive Biotechnologies shares in Q1 2021, an estimated $448K.
  • Pendal Group first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 3 quarters.
  • Pendal Group's Adaptive Biotechnologies position peaked at $448K in Q4 2020.
  • 248 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2021.

Based on Pendal Group's 13F filing for Q1 2021, filed 3 May 2021.